Inhibiting IGF-IR reduces the growth rate of normal cells, while its influence on some cancer cells is strong enough to cause apoptosis.40 Fedratinib is a JAK2 and FLT3 inhibitor approved by the US Food and Drug Administration to treat adults with myeloproliferative neoplasms. Here, FLT3 is linked to myeloproliferative neoplasm.